Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Diabetes Increasing in Asia: EASD President Prof. Smith
October 4, 2010
- MTPC Transfers 3 Long-Listed Products to Its Subsidiary
October 4, 2010
- Ono Applies for the Antiemetic Fosaprepitant
October 4, 2010
- EASD Welcomes GL Proposed by EMA
October 4, 2010
- BMS to Acquire ZymoGenetics through Tender Offer
October 4, 2010
- Dabigatran Receives Recommendation by FDA Committee: BI
October 4, 2010
- Otsuka to Codevelop OPA-6566 for Glaucoma with Acucela
October 4, 2010
- Daiichi Sankyo Completes Tender Offer for Zenotech Lab
October 4, 2010
- FDA Accepts NDA for Aricept Transdermal Patch: Eisai, Teikoku Seiyaku
October 4, 2010
- Takara Bio to Obtain Anticancer Agent from M's Science
October 4, 2010
- Japan's Own COI Disclosure System Necessary: Mr Hirai
October 4, 2010
- FDA Advisory Committee Not Recommend Approval for Lorcaserin: Eisai
October 4, 2010
- Kyowa Kirin Begins PIIb Trial for KW-0761 in Japan
October 4, 2010
- 2.4 Mil. Patients Suffer from Lumbar Canal Stenosis in Japan
October 4, 2010
- AnGes MG to Conduct Additional Trial for Collategene
October 4, 2010
- Peretinoin Reduces Risk of HCC Recurrence after Curative Therapy: Kowa
October 4, 2010
- New Anti-Epileptic Drug E Keppra: Otsuka, UCB
October 4, 2010
- NBI to Withdraw Alotec in Japan
October 4, 2010
- Pletaal Reduces Risk of Stroke, Hemorrhage in Japanese CI Patients: Otsuka
October 4, 2010
- ARB + CCB Combination Micamlo for Hypertension: NBI, Astellas
October 4, 2010
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…